Morgan Lewis

Life Sciences Protecting the Complete Life Cycle

For More Information

Read the Brochure

Life Sciences and Healthcare

New Resource

Healthcare Policy and Reform Resource Center

Life Sciences Deskbook

Compliance Resources

New Resource: Health Industry Transparency Compliance Resource Center

Emerging Business Tools

visit the Entrepreneur Resource Headquarters

Honors

LMG Life Sciences 2012 – Highly Recommended for Licensing and Collaboration, and for White Collar and Government Investigations. Recommended for FDA – Pharmaceuticals; Healthcare: Pricing and Reimbursement; Patent Prosecution; General Patent Litigation; Corporate; and Competition and Antitrust

PLCCross-border Quarterly 2012 Life Sciences Legal Market Review

  • Life Sciences Regulatory Super League - Ranked 8th among law firms worldwide

PLCCross-border Life Sciences Handbook 2011/12

  • U.S.:
    • Commercial and Partnering - Highly Recommended
    • Competition/Antitrust - Highly Recommended
    • Corporate - Recommended
    • Government Enforcement and Investigations - Highly Recommended
    • Regulatory - Recommended
    • Regulatory (Medical Devices) - Recommended
  • England: Regulatory - Recommended
  • Japan: Corporate and Commercial - Recommended

Chambers Global 2012: Global Life Sciences - Recommended - Band 3

Chambers USA 2012: National for Life Sciences - Band 3; Washington, D.C. for healthcare/ pharmaceutical/ medical products regulatory - Band 3

UK Legal 500 2010: London: Pharmaceuticals and Biotechnology

Best Lawyers in America 2011: Biotechnology and Healthcare Law Named

BioPharm Insight 2012

  • Ranked 3rd - Global League Table of Legal Advisers to Biotech and Pharma Licensing Agreements - Based upon Value
  • Ranked 4th - Global League Table of Legal Advisers to Biotech and Pharma Licensing Agreements - Based upon Volume
  • Ranked 10th - Legal Advisors to Biotech and Pharma Licensing Agreements: North America - Based upon Value
  • Ranked 5th - Legal Advisors to Biotech and Pharma Licensing Agreements: North America - Based upon Volume
  • Ranked 2nd - Legal Advisors to Biotech and Pharma Licensing Agreements: Europe - Based upon Value
  • Ranked 3rd - Legal Advisors to Biotech and Pharma Licensing Agreements: Europe - Based upon Volume
  • Ranked 2nd - Legal Advisors to Biotech and Pharma Licensing Agreements: Asia-Pacific - Based upon Value
  • Ranked 3rd - Legal Advisors to Biotech and Pharma Licensing Agreements: Asia-Pacific - Based upon Volume

U.S. News & World Report/Best Lawyers 2010: Ranked Tier 1 National Practice - Biotechnology

Clients

16 of the top 20 pharmaceutical companies

7 of the top 20 biotechnology companies

9 of the top 20 medical device companies

Practice Highlights

Related Events

Related News

05/15/13 Pharma Cos. Smell Victory In Push For Drug-Tracking System, Law360
Life Sciences partner Stephen Paul Mahinka is quoted.
04/30/13 Top 25 Portfolio Managers/Patent Prosecutors, Daily Journal
Jeffry S. Mann is listed as one of the "Top 25 Portfolio Managers/Patent Prosecutors" for 2013 by the Daily Journal.
04/11/13 Morgan Lewis Advises MEI Pharma on $15.2 Million Registered Offering of Common Stock
Morgan Lewis served as legal adviser to MEI Pharma, Inc. on registered offering of common stock.
View all news

Related Publications

05/08/13 HHS OIG Issues Report on Hospice General Inpatient Care Billing
Report makes no formal recommendations, but OIG notes that lengths of stay and frequency of general inpatient care are issues requiring further scrutiny.
04/29/13 CMS Aims to Grease the Reporting Wheels for Medicare Fraud and Abuse
Proposed rule would substantially increase rewards for fraud tips and enhance billing revocation authority.
04/17/13 HHS OIG Issues Revised Self-Disclosure Protocol
OIG touts substantial benefits of disclosing, provides greater detail for different types of disclosures, and captures 15 years of OIG Self-Disclosure Protocol experience.
View all publications

With more than 200 lawyers, scientists and other technical specialists who focus on the life sciences industry, we have one of the most comprehensive practices of any U.S. law firm. Unlike other law firms, we understand the scientific, business, and regulatory issues that our clients face and have expanded our practice to include more than 60 professionals with advanced life sciences degrees.

Our clients include many of the largest and most successful pharmaceutical companies in the world, as well as a long list of biotechnology companies, medical device manufacturers, nutritional companies, healthcare providers, renowned research and scientific institutions, and life sciences-focused investment banks and venture capital firms. As diverse as they are, these companies share a common need for comprehensive, integrated legal services that address all of the business issues and opportunities facing the industry.

Having expressly developed our capabilities to cover seamlessly the complete life sciences product lifecycle, we offer an unsurpassed mix of services that are critical to this industry. Our Life Sciences practice focuses on all important areas, from transactions and litigation to regulatory approvals and compliance and protection of intellectual property, as well as key supporting capabilities, including FDA and healthcare, patents and patent litigation, labor and employment law, Morgan Lewis Resources workplace training and immigration, and antitrust. As a full-service firm with offices in the financial and regulatory centers of central importance to the industry in the U.S., Europe and Asia, we are uniquely situated to provide counseling for the full range of business activities.